Yuan Bin, Zhao Hong, Xue Xiaofeng, Zhou Jin, Wang Xu, Han Ye, Zhang Lifeng, Guo Xiaobo, Zhi Qiaoming
Cancer Research Unit, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada.
Anticancer Agents Med Chem. 2016;16(4):407-13. doi: 10.2174/1871520615666150507120801.
B cell-specific Moloney murine leukemia virus integration site 1 (Bmi1) was identified as a biomarker of cancer stem cells, and over-expression of Bmi1 might enhance tumor aggressive clinical behavior in gastric cancer (GC). Our aim of this meta-analysis is to investigate the prognostic role and clinicopathological differences of Bmi1 in GC patients. A total of 6 studies up to September 2014 were included in our study. Our results showed that there were no relationships between Bmi1 expression and the gender (pooled OR=0.87, 95%CI=0.66-1.14, P=0.319, fixed effect), age (pooled OR=1.22, 95%CI=0.95-1.59, P=0.126, fixed effect) and differentiation (pooled OR=1.15, 95%CI=0.71-1.86, P=0.582, random effect) in GC patients. But high Bmi1 expression was significantly correlated with the clinical stage (pooled OR=3.04, 95%CI=1.31-7.07, P=0.010, random effect), tumor size (pooled OR=2.01, 95%CI=1.14-3.55, P=0.016, random effect), T classification (pooled OR=2.79, 95%CI=1.94-4.03, P<0.001, fixed effect), lymph node metastasis (pooled OR=2.24, 95%CI=1.47-3.39, P<0.001, random effect) and distant metastasis (pooled OR=5.05, 95%CI=1.29-19.70, P=0.020, random effect), and led to a poor overall survival (OS) in GC patients (RR=3.38, 95%CI=2.43-4.69, P<0.001, fixed effect). These findings suggested that Bmi1 might serve as a novel and effective prognostic biomarker in GC, and could be a promising emerging molecular target in GC therapy.
B细胞特异性莫洛尼鼠白血病病毒整合位点1（Bmi1）被确定为癌症干细胞的生物标志物，Bmi1的过表达可能会增强胃癌（GC）患者肿瘤的侵袭性临床行为。我们进行这项荟萃分析的目的是研究Bmi1在GC患者中的预后作用及临床病理差异。我们的研究纳入了截至2014年9月的6项研究。我们的结果显示，Bmi1表达与GC患者的性别（合并比值比=0.87，95%置信区间=0.66-1.14，P=0.319，固定效应）、年龄（合并比值比=1.22，95%置信区间=0.95-1.59，P=0.126，固定效应）和分化程度（合并比值比=1.15，95%置信区间=0.71-1.86，P=0.582，随机效应）均无关联。但Bmi1高表达与临床分期（合并比值比=3.04，95%置信区间=1.31-7.07，P=0.010，随机效应）、肿瘤大小（合并比值比=2.01，95%置信区间=1.14-3.55，P=0.016，随机效应）、T分期（合并比值比=2.79，95%置信区间=1.94-4.03，P<0.001，固定效应）、淋巴结转移（合并比值比=2.24，95%置信区间=1.47-3.39，P<0.001，随机效应）和远处转移（合并比值比=5.05，95%置信区间=1.29-19.70，P=0.020，随机效应）显著相关，并导致GC患者的总生存期（OS）较差（风险比=3.38，95%置信区间=2.43-4.69，P<0.001，固定效应）。这些发现表明，Bmi1可能是GC中一种新型有效的预后生物标志物，并且可能成为GC治疗中有前景的新兴分子靶点。
